What are the common and serious side effects of methotrexate and how should they be monitored?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 3, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Methotrexate Side Effects and Monitoring

Common Side Effects

The most frequently reported adverse reactions to methotrexate include gastrointestinal toxicity (nausea, vomiting, stomatitis, anorexia, abdominal distress), occurring in approximately 25-32% of patients, along with fatigue, malaise, and decreased resistance to infection. 1, 2 These common toxicities typically occur shortly after medication initiation and are often dose-related. 2

Management of Common Side Effects

  • Altering the dose, route, or frequency of administration can mitigate these effects – switching from oral to subcutaneous or intramuscular routes, or dividing the weekly dose into 2-3 administrations over 24 hours may improve tolerability. 2, 3
  • Taking methotrexate with food or at bedtime can reduce gastrointestinal symptoms. 2, 4
  • All patients must receive mandatory folic acid supplementation (1-5 mg daily, except on methotrexate day, or 5 mg weekly on a different day) to reduce gastrointestinal, hepatic, and hematologic toxicity without compromising efficacy. 2, 3

Serious and Life-Threatening Side Effects

Myelosuppression (Most Lethal Complication)

Bone marrow suppression accounts for the majority (67 of 164 cases) of methotrexate-associated fatalities, making hematologic toxicity the most dangerous complication. 3 This can manifest as leukopenia, neutropenia, thrombocytopenia, pancytopenia, or aplastic anemia. 1

  • Myelosuppression can occur after even a single dose and at any time during treatment, typically in patients with at least one risk factor. 4
  • If white blood cells <3.5×10⁹/L or neutrophils <2×10⁹/L, methotrexate should be withheld until counts recover. 3
  • For severe neutropenia (<1×10⁹/L), filgrastim (G-CSF) 5 mcg/kg/day subcutaneously should be administered to accelerate myeloid recovery. 3, 5

Hepatotoxicity

Liver enzyme elevations are common (48.9% above upper limit of normal), but methotrexate-induced fibrosis/cirrhosis is rare (1.3% severe fibrosis, 0.5% cirrhosis after mean 4.1 years). 2 Transient elevations within 3-4 days after dosing are frequent and usually not cause for concern. 4, 1

  • Methotrexate should be stopped if there is a confirmed increase in ALT/AST greater than three times the upper limit of normal (ULN), but may be reinstituted at a lower dose following normalization. 2
  • If ALT/AST levels are persistently elevated up to three times ULN, the dose should be adjusted; diagnostic procedures (including GI consultation and/or transient elastography) should be considered for persistent elevation after discontinuation. 2
  • Routine liver biopsy is not necessary, as cirrhosis risk is much lower than previously thought. 3

Pulmonary Toxicity

Pulmonary fibrosis accounts for 30 of 164 methotrexate-associated fatalities, making it the second most common cause of methotrexate-related death. 3 Methotrexate-induced pneumonitis presents with dyspnea, dry nonproductive cough, and fever. 2, 3

  • A baseline chest x-ray should be obtained for all patients starting methotrexate. 3, 1
  • Pulmonary toxicity is more common in rheumatoid arthritis than psoriasis patients. 2
  • Symptoms usually resolve with discontinuation of methotrexate. 3

Infection and Immunosuppression

Given the immunosuppressive nature of methotrexate, treatment increases the risk of infection, reactivation of latent tuberculosis and hepatitis, and lymphoproliferative disorders (especially Epstein-Barr virus-associated B-cell lymphoma). 2, 1

  • Hepatitis B and C screening and baseline tuberculosis testing should be considered based on individual risk factors. 2
  • Opportunistic infections, including Pneumocystis carinii pneumonia (most common), have been reported. 1

Critical Risk Factors for Toxicity

Renal insufficiency is the primary risk factor for methotrexate toxicity due to 85% renal excretion and impaired drug clearance. 2, 3, 4 Other major risk factors include:

  • Advanced age (>50-70 years) significantly increases toxicity risk. 3, 4
  • Lack of folate supplementation is a common preventable risk factor. 3, 4
  • Hypoalbuminemia increases toxicity risk. 3, 4
  • Methotrexate dosing errors (daily instead of weekly dosing) can lead to severe toxicity. 3, 4

Dangerous Drug Interactions

NSAIDs reduce renal elimination of methotrexate, which is particularly dangerous and has resulted in deaths from severe hematologic and gastrointestinal toxicity when combined with high-dose methotrexate. 1 Caution should be used even with lower doses. 1

  • Trimethoprim-sulfamethoxazole is absolutely contraindicated with methotrexate due to severe bone marrow suppression risk from both drugs being folic acid antagonists. 3, 4
  • Other high-risk interactions include salicylates, sulfonamides, phenytoin, penicillins, and probenecid, which decrease methotrexate binding to albumin or reduce renal tubular excretion. 1

Monitoring Requirements

Initial Phase (First 3-6 Months)

When starting methotrexate or increasing the dose, complete blood count with differential, ALT/AST, creatinine, and albumin should be performed every 1-1.5 months until a stable dose is reached. 2, 3

  • Baseline assessment should include complete blood count with differential and platelet counts, hepatic enzymes, renal function tests, chest x-ray, and consideration of hepatitis B/C and tuberculosis screening. 2, 1

Maintenance Phase

After stabilization, complete blood count and liver function tests should be performed every 1-3 months (or every 3-6 months per some guidelines). 2, 3, 1

  • Clinical assessment for side effects and risk factors should be performed at each visit. 2
  • More frequent monitoring is indicated during periods of increased risk (e.g., dehydration, renal impairment, drug interactions). 1

Management of Methotrexate Toxicity/Overdose

Immediate Antidote

Leucovorin (folinic acid) administration is the cornerstone of treatment and must be initiated immediately upon suspicion of methotrexate toxicity, as efficacy diminishes dramatically after 24 hours. 3, 5 This is life-saving and time-critical. 3

  • Initial dosing: 10-100 mg/m² IV (approximately 15 mg for average adult) immediately, followed by doses every 6 hours until toxicity resolves or methotrexate levels fall below 0.05 µmol/L. 3, 5
  • Do not confuse folic acid with folinic acid (leucovorin) – only leucovorin bypasses methotrexate's metabolic block and serves as an effective antidote. 3

Additional Measures

  • For recent oral ingestion (≥1 mg/kg within 1 hour), administer activated charcoal immediately. 3, 5
  • Initiate aggressive IV hydration (3 L/day) to enhance renal elimination. 3, 5
  • Perform urinary alkalinization with sodium bicarbonate to maintain urine pH ≥7.0 and prevent methotrexate precipitation in renal tubules. 3, 5

Common Pitfalls to Avoid

  • Delaying leucovorin administration is a critical error – efficacy is doubtful if initiated >24 hours after last methotrexate dose. 3
  • Mistaken daily use of the recommended weekly dose has led to fatal toxicity – prescriptions should not be written on a PRN basis, and patients must be counseled that dosing is weekly only. 1
  • Assuming low serum methotrexate levels exclude toxicity is incorrect – treat based on clinical presentation. 3
  • Stopping antibiotics prematurely when infection occurs – methotrexate should remain discontinued until infection resolves and antibiotic course is complete. 3

References

2
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

3
Guideline

Management of Methotrexate Toxicity

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

4
Guideline

Methotrexate Side Effects and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

5
Guideline

Management of Methotrexate Toxicity

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

Which medications should be avoided when taking methotrexate?
What verbal teaching points should I give a relative who will administer a weekly subcutaneous methotrexate (0.45 mL prefilled syringe) injection into the posterior upper arm of a needle‑phobic patient?
What important information should be disclosed to a patient when prescribing methotrexate (MTX)?
Is massage contraindicated for a patient receiving methotrexate therapy?
What is the safe cumulative dose of methotrexate (MTX) for a patient with rheumatoid arthritis (RA) and what are the monitoring requirements?
In a 31-year-old man who presented with diabetic ketoacidosis and now has evidence of hemolysis (low haptoglobin, elevated lactate dehydrogenase, reticulocytosis) with a negative direct antiglobulin test and a normal peripheral smear, what is the appropriate next step in management?
Is end‑stage renal disease (ESRD) a contraindication to intracavernosal injection therapy for erectile dysfunction?
What is the most likely diagnosis and appropriate management for an 11‑year‑old male with hemoglobin 13.7 g/dL, hematocrit 40.9 %, mean corpuscular volume (MCV) 79 fL (microcytosis), creatinine 0.5 mg/dL, and ferritin 21 ng/mL?
For a woman with a QTc of 497 ms at high risk for torsades de pointes, which outpatient non‑selective beta‑blocker is recommended and what initial and titrated dosing regimen should be used?
What is the appropriate management of symptomatic uremia?
In an 82-year-old woman with mild dementia and a recent transient ischemic attack who presents with acute headache, right-sided facial, arm, and leg weakness, mild fever, blood pressure 152/86 mmHg, and MRI showing lobar microbleeds in the left periventricular region, frontal lobe, and left cerebellum, which of the following is the most likely diagnosis: infectious vasculitis, hypertensive arteriopathy, cerebral venous sinus thrombosis, or cerebral amyloid angiopathy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question